Loading organizations...
§ Private Profile · Singapore, Central Region, Singapore
Biotechnology company developing therapeutics for aging and age-related diseases, utilizing physics-informed AI to identify drug targets.
Singapore-based Gero is a biotechnology company that develops therapeutics targeting the root causes of aging and age-related diseases using physics-informed artificial intelligence models. The organization trains its proprietary algorithms on longitudinal datasets containing over 100 million patient records to separate irreversible aging mechanisms from reversible disease processes. Operating a dual business model, the firm advances its own internal pipeline of anti-aging drugs while collaborating with major pharmaceutical corporations to identify novel targets for fibrotic conditions, neurodegeneration, and oncology. Additionally, the enterprise creates digital biomarkers for clinical applications through its GeroSense platform. Gero has raised $17 million in total venture funding to date, which includes a recent $6 million Series A extension backed by lead investors Melnichek Investments, VitaDAO, and Leonid Lozner. The company was founded in 2015 by Peter Fedichev and Maxim Kholin.
Gero has raised $8.2M across 2 funding rounds.
Gero has raised $8.2M in total across 2 funding rounds.
Gero has raised $8.2M in total across 2 funding rounds.
Gero's investors include Yury Melnichek, Misha Lyalin, Leonid Lozner, Eleanor Davies.
Gero has raised $8.2M across 2 funding rounds. Most recently, it raised $6.0M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2023 | $6M Series A | Yury Melnichek | Misha Lyalin, Leonid Lozner, Eleanor Davies | Announced |
| Aug 4, 2020 | $2.2M Series A | Yury Melnichek | — | Announced |
Gero is a biotechnology company developing AI-driven therapeutics to target the root causes of aging and age-related diseases, aiming to double healthy human lifespan within a generation.[3][1][4] It builds foundational AI models trained on over 100 million patient records to map aging trajectories, distinguish irreversible aging from reversible processes, and identify drug targets for chronic conditions like frailty and immuno-senescence.[3][1] Gero serves pharmaceutical partners (e.g., Chugai, Pfizer) through collaborations and advances in-house anti-aging interventions, solving the problem of entropy-driven functional decline by restoring systemic resilience.[4][3] Recent momentum includes a $6M Series A extension led by Melnichek Investments, peer-reviewed publications, and deals like Chugai's up-to-$250M antibody development partnership, positioning it for a $30M+ financing round.[1][4]
Gero was founded by Peter Fedichev (CEO) and co-founders with expertise in physics and machine learning, emerging from first-principles research into human aging using real-world longitudinal data.[1][3] The idea stemmed from applying physics-guided frameworks—grounded in thermodynamics—to unbiasedly explore biology, separating true aging (whole-life entropy) from disease-related frailty.[4][1] Early traction came from developing proprietary large health models (LHM), publishing in peer-reviewed journals, and validating immuno-senolytic assets that extended mouse lifespan and reduced senescence markers.[1][4] Pivotal moments include VitaDAO support and the 2023 $6M raise, accelerating in-house and partnered drug discovery.[1][4]
(Note: A separate Thailand-based Gero Technology focuses on infrastructure like energy and buildings, unrelated to this biotech firm.[2][5])
Gero rides the convergence of scalable longitudinal health data, generative AI, and longevity biotech, timing perfectly with aging populations driving $trillion healthcare costs.[1][3][4] Market forces like exploding molecular datasets and AI's drug discovery efficiency favor its platform, which simplifies aging into druggable phenotypes (frailty vs. true aging) for broad interventions.[4] It influences the ecosystem by partnering with giants like Chugai and Pfizer, accelerating AI-biopharma adoption, and via VitaDAO fostering decentralized longevity funding—positioning Gero as a leader in a competitive field blending physics, AI, and therapeutics.[4][1]
Gero's momentum—fresh funding, pharma deals, and validated science—sets it up to advance clinical assets targeting aging deceleration, with a $30M+ round likely fueling human trials.[4][1] Trends like AI-scaled data and entropy-focused geroscience will amplify its edge, evolving its influence from pioneer to category leader as longevity therapeutics mature. By rewriting aging's physics, Gero could deliver the decades of healthy life its mission promises, transforming biotech from disease treatment to prevention.[3]